Even if Selank cannot completely supplant benzodiazepine treatment for some people, there is evidence that the peptide can augment the action of phenazepam, which is used to treat anxiety disorders
If the FDA ultimately issues a final determination against listing, compounders would lose any viable legal pathway and substances could be re-nominated in future PCAC cycles, or challenged in court, as happened with previously restricted peptides
Several attempts were made to establish SAR for BCRP interaction, however, many analysis methods were based on the datasets of inhibitors (Saito et al
The most commonly applied BPC-157 protocol for acute injury repair runs four to six weeks of daily administration, followed by a rest period of equal duration before reassessment
Both are on the July 2026 Pharmacy Compounding Advisory Committee agenda for 503A compounding review, which is a separate regulatory question from approval